Covidien has announced it has received FDA clearance to market the Covidien Nellcor Bedside SpO2 Patient Monitoring System, according to a news release.
The Nellcor Bedside SpO2 system includes the company's OxiMax technology and is designed to continuously monitor SpO2 and pulse rate for adult, pediatric and neonatal patients.
"We are pleased to announce the new Covidien Nellcor Bedside SpO2 Patient Monitoring System is approved for commercial release in the United States," said Robert White, president, respiratory and monitoring solutions, Covidien, in the release. "Healthcare professionals on the general care floor, and in other lower- acuity areas of the hospital, need critical patient information at their fingertips so they can respond quickly to health threats. By giving them ready access to a patient's respiratory history, the system allows them to focus on delivering efficient, high-quality care, not gathering and managing data."
Covidien has its U.S. headquarters in Mansfield, Mass.
Related Articles on FDA Clearances:
Siemens Receives FDA Clearance for MRI System
Roche Receives FDA Clearance for Insulin Pump Therapy System
GE Healthcare Receives FDA Clearance for Cardiac Spectral CT